Manufacturing

Articles

Pfizer invested $68.5 million in a facility in Durham, NC.

Pfizer Opens Gene Therapy Clinical Manufacturing Facility 

SKAN’s new Cellana isolator is designed for GMP manufacturing of ATMPs.

New Isolator for Cell and Gene Therapy Manufacturing

Guide addresses challenges of applying GMPs to autologous cell therapy manufacturing.

ISPE Publishes Guide for ATMP Facilities

A new Cytiva FlexFactory platform will be installed at Taiyo Pharma Tech’s site in Osaka, Japan.

Taiyo Pharma Tech Adds Gene Therapy Capacity in Japan

David Smith is CMO manager at Glide Pharmaceutical Technologies Ltd.

Courtney LeBlon, PhD, Director of Technical Operations, Ori Biotech.

Stephen Shapka, PhD, Lead Automation Engineer, Ori Biotech.

Analytical methods need a boost to ensure quality control for cell and gene therapies.

Contamination Control for Cell and Gene Therapies Needs New Analytics

Feliza Mirasol is the science editor for 

Chris Spivey is director of Industry Relations and Strategic Partnership, MJH Life Sciences.

Part 2—Industry experts from MilliporeSigma, Lonza, Astrea Bioseparations, and Sartorius provide insight and examples about solving critical challenges in both analytics and process development for emerging therapies.

Advances in Molecule Characterization and Biomanufacturing for Emerging Therapies: Part 2

Part 1—Industry experts from MilliporeSigma, Lonza, Astrea Bioseparations, and Sartorius discuss key issues affecting the development of emerging biotherapies.

Advances in Molecule Characterization and Biomanufacturing for Emerging Therapies: Part 1 

The research collaboration between Sartorius and Matica Biotechnology will aim to optimize PAT technologies, automation software, and single-use platforms for large-scale viral vector production.

Sartorius Forms Joint Research Pact with Matica Bio for Advanced Viral Vector Manufacturing Technology

The $691 million deal will see Vertex use Mammoth’s systems to discover and develop in-vivo gene-editing therapies.

Vertex and Mammoth Enter into Gene-Editing Partnership Worth Up to $691 Million

Jennifer Markarian is manufacturing reporter for Pharmaceutical Technology.

A new GMP facility in Raleigh, NC, and a starting materials facility in Paris, France, give Cellectis end-to-end, in-house manufacturing capacity for its UCART product candidates.  

Manufacturing, Gene Therapies